logo-loader
viewImugene Ltd

Imugene receives $4.13 million R&D tax incentive boost for commercial and clinical milestones

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019.

Professor Fong is the inventor of the technology and spoke about the importance it will make to patients with a trial underway and making good progress.

The CEO also updates the market on a $4.13 Australian Government R&D tax incentive to help further develop commercial and clinical milestones.

Quick facts: Imugene Ltd

Price: 0.037 AUD

ASX:IMU
Market: ASX
Market Cap: $134.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

2 min read